Recce Pharmaceuticals Advances Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd is pioneering a new class of synthetic anti-infectives to combat antibiotic-resistant bacteria and viruses. Their innovative pipeline, including RECCE 327 in clinical trials, has gained recognition from WHO and FDA, with the latter granting Fast Track Designation and promising market exclusivity. The company’s proprietary manufacturing process supports these clinical advancements, targeting critical gaps in current treatment options.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.